Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon Beta-1a in patients with multiple sclerosis.
Is multiple sclerosis an autoimmune disease?
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Combined EPR and Molecular Modeling Study of PPI Dendrimers Interacting with Copper Ions: Effect of Generation and Maltose Decoration.
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide.
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
Multiple sclerosis and sexual dysfunction.
Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study.
The Arabic version of the Mayo-Portland Adaptability Inventory 4: a validation study.
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.
Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System.
Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
Human papillomavirus vaccination, induced autoimmunity, and neuromyelitis optica.
Naltrexone prescribing information
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
The prospects of minocycline in multiple sclerosis.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
The histaminergic network in the brain: basic organization and role in disease.
A signal-to-noise-ratio-based analysis of multifocal visual-evoked potentials in multiple sclerosis risk assessment.
Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave Dreams Study (Brain Venous Drainage Exploited Against Multiple Sclerosis): study protocol for a randomized controlled trial.
A cross-sectional study examining multiple mobility device use and fall status among middle-aged and older adults with multiple sclerosis.
Pages
« first
‹ previous
…
141
142
143
144
145
146
147
148
149
…
next ›
last »